Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation

Abstract Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huashan Gao, Qian Zhao, Shanshan Tang, Kaiying Li, Fujian Qin, Ziwei Song, Yi Pan, Liang Jin, Yanfeng Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e447863a899842fc87907b30a959e33f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e447863a899842fc87907b30a959e33f
record_format	dspace
spelling	oai:doaj.org-article:e447863a899842fc87907b30a959e33f2021-12-02T14:11:32ZContinuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation10.1038/s41598-021-83201-42045-2322https://doaj.org/article/e447863a899842fc87907b30a959e33f2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83201-4https://doaj.org/toc/2045-2322Abstract Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type 1 diabetes through immunomodulation. Therefore, we designed a new dual-functional PGLP-1-VP, which is expected to combine the anti-inflammatory effect of PGLP-1 and the immunomodulatory effect of VP peptide. In streptozotocin-induced hyperglycemic mice model, we demonstrated that PGLP-1-VP can act as a GLP-1R agonist to improve hyperglycemia and increase insulin sensitivity. In the NOD mouse model, PGLP-1-VP treatment reduced morbidity, mortality, and pancreatic inflammation, and showed superior effect to PGLP-1 or VP treatment alone, confirming that PGLP-1-VP may act as a dual-function peptide. PGLP-1-VP provided immunomodulatory effect through increasing Th2 cell percentage and balancing the ratio of Th2/Th1 in spleen and PLN, similar to P277 and VP. Additionally, PGLP-1-VP and PGLP-1 act the anti-inflammation by increasing Treg cells and TGF-β1 content like DPP-IV inhibitor. Taken together, our data shows that the dual-functional PGLP-1-VP reduces morbidity and mortality in the NOD model, suggesting a potential role in preventing and treating type 1 diabetes.Huashan GaoQian ZhaoShanshan TangKaiying LiFujian QinZiwei SongYi PanLiang JinYanfeng ZhangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Huashan Gao Qian Zhao Shanshan Tang Kaiying Li Fujian Qin Ziwei Song Yi Pan Liang Jin Yanfeng Zhang Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
description	Abstract Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type 1 diabetes through immunomodulation. Therefore, we designed a new dual-functional PGLP-1-VP, which is expected to combine the anti-inflammatory effect of PGLP-1 and the immunomodulatory effect of VP peptide. In streptozotocin-induced hyperglycemic mice model, we demonstrated that PGLP-1-VP can act as a GLP-1R agonist to improve hyperglycemia and increase insulin sensitivity. In the NOD mouse model, PGLP-1-VP treatment reduced morbidity, mortality, and pancreatic inflammation, and showed superior effect to PGLP-1 or VP treatment alone, confirming that PGLP-1-VP may act as a dual-function peptide. PGLP-1-VP provided immunomodulatory effect through increasing Th2 cell percentage and balancing the ratio of Th2/Th1 in spleen and PLN, similar to P277 and VP. Additionally, PGLP-1-VP and PGLP-1 act the anti-inflammation by increasing Treg cells and TGF-β1 content like DPP-IV inhibitor. Taken together, our data shows that the dual-functional PGLP-1-VP reduces morbidity and mortality in the NOD model, suggesting a potential role in preventing and treating type 1 diabetes.
format	article
author	Huashan Gao Qian Zhao Shanshan Tang Kaiying Li Fujian Qin Ziwei Song Yi Pan Liang Jin Yanfeng Zhang
author_facet	Huashan Gao Qian Zhao Shanshan Tang Kaiying Li Fujian Qin Ziwei Song Yi Pan Liang Jin Yanfeng Zhang
author_sort	Huashan Gao
title	Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
title_short	Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
title_full	Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
title_fullStr	Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
title_full_unstemmed	Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
title_sort	continuous stimulation of dual-function peptide pglp-1-vp inhibits the morbidity and mortality of nod mice through anti-inflammation and immunoregulation
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e447863a899842fc87907b30a959e33f
work_keys_str_mv	AT huashangao continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT qianzhao continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT shanshantang continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT kaiyingli continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT fujianqin continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT ziweisong continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT yipan continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT liangjin continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT yanfengzhang continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation
_version_	1718391875912597504

Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation

Ejemplares similares